Anti-inflammatory and anti-aging cosmetic capable of being used after medical art

Abstract

The invention discloses an anti-inflammatory and anti-aging cosmetic capable of being used after medical art, belongs to the field of cosmetics, and particularly relates to a liquid compound which is prepared from a utility agent, an auxiliary agent and water and can be used in the cosmetics, and the auxiliary agent further comprises a thickening agent, a humectant and a preservative. The utility agent at least comprises an active matter, the active matter comprises at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE lipidosome, a bifidus yeast fermentation product and a lysate, and an active agent can also be added into the utility agent. The liquid compound obtained by the invention has the advantages of no cytotoxicity, good safety, capability of promoting cell proliferation, good anti-inflammatory effect, good anti-aging effect, no irritation to skin and good anti-inflammatory effect after medical treatment.

Description

Technical Field

[0001] The invention belongs to the field of cosmetics, and in particular relates to an anti-inflammatory and anti-aging cosmetic that can be used after medical aesthetics. Background Art

[0002] With people's constant pursuit of beauty, the field of medical cosmetology has ushered in unprecedented development opportunities. Various minimally invasive beauty technologies have sprung up, among which mesodermal beauty, photoelectric beauty and other technologies are favored for their remarkable effects. These technologies effectively solve a series of problems such as skin spots, aging, acne and dryness through different mechanisms of action, making the skin glow. However, while bringing beauty, minimally invasive medical beauty surgery will inevitably have a certain impact on the skin barrier. As an important protective layer of the human body, once damaged, the skin barrier will not only affect the health of the skin, but also may cause the emergence of various skin problems. For some patients with sensitive skin, the harm caused by the release of inflammatory factors during the repair process is more lasting. Therefore, after minimally invasive medical beauty surgery, the use of barrier repair products has become an indispensable part. At the same time, inflamed skin is more susceptible to external stimuli than normal skin, inducing inflammation, releasing free radicals to participate in the inflammation and glycation process, forming a vicious cycle of inflammation-glycation-oxidation, and making the skin more susceptible to aging. Therefore, the anti-aging effect on inflamed skin is as important as anti-inflammatory repair. However, the Class II dressings commonly used after medical aesthetics mainly play the role of physical barriers by forming a protective layer on the wound surface. CN117085174A discloses a liquid dressing for wound care after medical aesthetics and its preparation method, but the Class II dressing does not have pharmacological effects and cannot be degraded and absorbed. It can only limit the use of macromolecular moisturizing substances and cannot be truly absorbed through the skin. After the skin wound heals quickly, the therapeutic effect of Class II dressings is no longer significant. Conventional cosmetics with anti-aging effects lack research on the population suitable for the inflammatory period after medical aesthetics.

[0003] The repair process after medical aesthetic surgery is divided into three stages. In the acute inflammatory phase 24 hours after surgery, immune cells rapidly infiltrate the wound within minutes of tissue damage, among which neutrophils and macrophages are the most important effector cells in the inflammatory phase. These immune cells release a variety of cytokines and chemokines to recruit cells from the blood and the edge of the injury into the wound; at the same time, the secreted cytokines can further promote cell proliferation at the site of injury. In addition, immune cells secrete a variety of proteases and reactive oxygen species to resist the invasion of pathogenic microorganisms and remove damaged cells. Although early inflammatory response is conducive to wound healing, many studies have shown that an increase in the number of immune cells in the injured area or a prolonged inflammatory response will cause a disorder in the injury repair process, ultimately leading to long-term non-healing wounds or pathological scar formation. This is mainly due to the continuous production of ROS in the injured area, which destroys the cell structure and function, causing a disorder in the normal skin repair process. New tissue begins to form 2 to 10 days after skin injury, and repair enters the proliferation phase. This stage mainly includes angiogenesis, granulation tissue formation and re-epithelialization. Angiogenesis is the key to wound repair. Macrophages and damaged endothelial cells release FGF-2 and VEGF to promote angiogenesis. Subsequently, capillaries sprout and infiltrate the injured site, forming granulation tissue with fibroblasts and immune cells to provide nutrition and oxygen for cell metabolism. Finally, growth factors such as EGF and TGF-β stimulate the proliferation and migration of keratinocytes at the edge of the injury, so that the damaged dermis can be re-epithelialized. After the re-epithelialization process is completed, keratinocytes differentiate and restore the barrier function of the epidermis. At the same time, dermal fibroblasts proliferate and migrate to the injured site, producing a large amount of extracellular matrix. At the end of this stage, growth factors (TGF-β) or mechanical pressure stimulate some fibroblasts to differentiate into myofibroblasts, and myofibroblasts express actin (α-smooth) to promote wound contraction. The third stage is the tissue remodeling period, which generally occurs 2 to 3 weeks after injury and can last for many years. During this stage, the signal of injury activation gradually weakens. Once the wound is re-epithelialized, keratinocytes stop proliferating and migrating, and then begin to differentiate. The blood vessels in the new tissue gradually mature to form a functional network. Most endothelial cells, inflammatory cells, fibroblasts, and myofibroblasts undergo apoptosis or withdraw from the wound. The granulation tissue formed during the early repair process is gradually replaced by the newly formed collagen-rich dermal matrix. It is worth noting that normal skin tissue is mainly composed of type III collagen forming a basket weave structure, while the injured area is reconstructed into coarser type I collagen and forms a dense parallel structure. Epidermal appendages, such as hair follicles and sebaceous glands, generally cannot regenerate during this process. Therefore, the newly formed tissue is usually different from healthy tissue and manifests as a scar, with decreased elasticity and tensile strength as the main characteristics. Summary of the invention

[0004] The present invention combines the usage scenarios and functional defects of Class II excipients and conventional cosmetics, and proposes the concept of cosmetic-device combination. Class II sterile dressing products are used in the extreme inflammatory period after medical aesthetics to inhibit the occurrence of acute inflammation and promote wound healing. They are then paired with mild and soothing anti-aging products to meet anti-aging needs.

[0005] The purpose of the present invention is to provide an anti-inflammatory and anti-aging cosmetic that is non-cytotoxic, has good safety, promotes cell proliferation, has good anti-inflammatory effect, good anti-aging effect, is non-irritating to the skin, and has good anti-inflammatory effect after medical aesthetics, and can be used for medical aesthetics.

[0006] The technical solution adopted by the present invention to achieve the above-mentioned purpose is: A liquid compound comprises: an agent and water, wherein the content of the agent in the liquid compound is 0.003-6.0wt%; the agent comprises an active substance, wherein the active substance comprises at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom peptide, carnosine, palmitoyl tripeptide-1, palmitoyl tripeptide-5, ACE liposome, bifid yeast fermentation product and lysate. The liquid compound in the present invention is a product with both anti-inflammatory and anti-aging effects and can be used for daily skin care and medical aesthetics. It can not only make up for the anti-aging effect of the second type of dressing, but also meet the mild anti-inflammatory effect of cosmetics. The formula ingredients are streamlined and the process operation is simple.

[0007] Preferably, the liquid compound further comprises a thickener, the thickener comprises at least one of carbomer, xanthan gum and sclerotium gum, and the content of the thickener in the liquid compound is 0.01-1.0 wt %.

[0008] Preferably, the liquid composite further comprises a humectant, which comprises at least one of glycerol, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, carboxymethyl cellulose and chitosan, and the content of the humectant in the liquid composite is 1-20 wt %.

[0009] Preferably, the liquid compound further comprises a preservative, the preservative is a raspberry ketone system, and the content of the preservative in the liquid compound is 0.1-1.0 wt %.

[0010] Preferably, the effector further comprises an active agent, the active agent comprises a succinate derivative, the succinate derivative is made of 2-aminoethanol hydrogen sulfate and maleate, and the maleate is made of trimethylolpropane and maleic anhydride. The present invention finds that the succinate derivative can be compounded with the active substance and used together, and under the action of other adjuvants, the anti-aging and anti-inflammatory effects of the obtained liquid complex can be improved, and it has no cytotoxicity, good safety and no irritation to the skin.

[0011] More preferably, the content of the active agent in the liquid compound is 0.003-1.0 wt %; or, The content of active matter in the liquid compound is 0.003-5.0 wt %.

[0012] More preferably, in the preparation of maleate, trimethylolpropane and maleic anhydride are mixed and reacted to obtain maleate, and the amount of trimethylolpropane used is 50-150 wt % of the maleic anhydride.

[0013] More preferably, in the preparation of the succinate derivative, 2-aminoethanol hydrogen sulfate and maleate are mixed in an ethanol aqueous solution containing sodium hydroxide, and the succinate derivative is reacted; the amount of 2-aminoethanol hydrogen sulfate used is 20-30wt% of the maleate.

[0014] The invention discloses use of the liquid complex in preparing anti-inflammatory cosmetics and / or anti-aging cosmetics and / or non-irritating products.

[0015] Preferably, in the preparation of maleic acid ester, trimethylolpropane is added to maleic anhydride at 60-80°C, and the reaction is carried out at 85-95°C for 2-8 hours. After the reaction is completed, maleic acid ester is obtained.

[0016] More preferably, in the preparation of maleate, the amount of trimethylolpropane used is 50-150 wt % of maleic anhydride.

[0017] Preferably, in the preparation of the succinate derivative, sodium hydroxide and 2-aminoethanol hydrogen sulfate are added to deionized water, stirred and mixed, and then maleate and ethanol are added at 30-50° C. and reacted for 2-8 hours. After the reaction is completed, the precipitate is cooled and filtered, washed, and distilled under reduced pressure to obtain the succinate derivative.

[0018] More preferably, in the preparation of the succinate derivative, the amount of sodium hydroxide used is 30-50 wt % of the deionized water.

[0019] More preferably, in the preparation of the succinate derivative, the amount of 2-aminoethanol hydrogen sulfate used is 40-60 wt % of deionized water.

[0020] More preferably, in the preparation of the succinate derivative, the amount of 2-aminoethanol hydrogen sulfate used is 20-30 wt % of the maleate.

[0021] More preferably, in the preparation of the succinate derivative, the amount of anhydrous ethanol used is 100-200 wt % of the maleate.

[0022] The invention discloses a method for preparing a liquid composite, comprising: adding a thickener into water, then adding a moisturizer and a preservative, homogenizing at 70-90°C for 2-10 minutes, cooling to 20-50°C after the homogenization, then adding an effector, stirring and mixing evenly, cooling to room temperature, and obtaining a liquid composite.

[0023] Preferably, the benefit agent comprises an active substance, the active substance comprises at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom peptide, carnosine, palmitoyl tripeptide-1, ACE liposome, bifida yeast fermentation product and lysate, and the content of the active substance in the liquid complex is 0.003-5.0wt%.

[0024] Preferably, the thickener comprises at least one of carbomer, xanthan gum and sclerotium gum, and the content of the thickener in the liquid compound is 0.01-1.0 wt %.

[0025] Preferably, the moisturizing agent comprises at least one of glycerol, 1,2-pentanediol, dipropylene glycol, carboxymethyl cellulose and chitosan, and the content of the moisturizing agent in the liquid composite is 1-20 wt %.

[0026] Preferably, the preservative is a raspberry ketone system, and the content of the preservative in the liquid compound is 0.1-1.0 wt %.

[0027] Preferably, the balance of the reagent in the liquid composition is water.

[0028] Preferably, the utility agent also includes an active agent, and the content of the active agent in the liquid composite is 0.003-1.0wt%. The active agent includes a succinate derivative and / or alginate-1,2-propylene glycol ester. The present invention can also add alginate-1,2-propylene glycol ester as an active agent, and alginate-1,2-propylene glycol ester and a succinate derivative are used as active agents. Under the action of the active substance and the adjuvant, the obtained liquid composite has better anti-aging and anti-inflammatory effects, no cytotoxicity, good safety and no irritation to the skin.

[0029] More preferably, the active agent comprises a succinate derivative, and the content of the succinate derivative in the liquid compound is 0.003-0.5 wt %.

[0030] More preferably, the active agent further comprises 1,2-propylene glycol alginate, and the content of 1,2-propylene glycol alginate in the liquid composite is 0.003-0.5 wt %.

[0031] Without affecting the effect of the present invention, the present invention may also add reagents harmless to the human body, such as EDTA, disodium EDTA, amino acids and the like. Amino acids include arginine and the like.

[0032] The present invention uses an agent, an adjuvant and water to prepare a liquid complex, which can be used in cosmetics. The adjuvant also includes a thickener, a moisturizer and a preservative; the agent in the present invention includes at least an active substance, and the active substance includes at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom peptide, carnosine, palmitoyl tripeptide-1, ACE liposome, bifida yeast fermentation product and lysate, and the liquid complex containing the above active substances has excellent anti-inflammatory and anti-aging effects; further, the present invention can also add an active agent, and the use of the active agent, under the action of the active substance and the adjuvant, the obtained liquid complex has a more excellent effect. The liquid complex obtained by the present invention has no cytotoxicity, good safety, and has the effects of promoting cell proliferation, good anti-inflammatory effect, good anti-aging effect, no irritation to the skin, and good anti-inflammatory effect after medical aesthetics. Therefore, the present invention is a non-cytotoxic, safe, cell proliferation-promoting, anti-inflammatory effect, good anti-aging effect, no irritation to the skin, and good anti-inflammatory effect after medical aesthetics. It can be used for anti-inflammatory and anti-aging cosmetics after medical aesthetics. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 The figure shows the expression results of cellular inflammatory factors.

[0034] Figure 2 The figure shows the expression results of cellular inflammatory factors.

[0035] Figure 3 The figure shows the expression results of cellular inflammatory factors.

[0036] Figure 4 The figure shows the expression results of cellular inflammatory factors.

[0037] Figure 5 This is the expression diagram of the inflammatory factor MIF.

[0038] Figure 6 The results of relative gene expression are shown in Figure 2 .

[0039] Figure 7 The results of relative gene expression are shown in Figure 2 .

[0040] Figure 8 The results of relative gene expression are shown in Figure 2 .

[0041] Fig. 9 The results are shown in Figure 2. The relative gene expression results are shown in Figure 2.

[0042] Fig.10 This is the relative expression level of NFE2L2 gene. DETAILED DESCRIPTION

[0043] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0044] The following first describes the concepts involved in the present application in conjunction with the accompanying drawings. It should be noted that the following description of each concept is only to make the content of the present application easier to understand, and does not limit the scope of protection of the present application; at the same time, the embodiments and features in the embodiments of the present application can be combined with each other in the absence of conflict. The present application will be described in detail with reference to the accompanying drawings and in conjunction with the embodiments.

[0045] Example 1: A method for preparing a liquid composite Preparation of liquid compound: Add thickener to water, then add moisturizer and preservative, homogenize at 80°C for 3 minutes, cool to 40°C after homogenization, then add benefit agent, stir and mix evenly, cool to room temperature to obtain liquid compound. The thickener is carbomer, the moisturizer is glycerin, the preservative is a raspberry ketone system, the effector includes active ingredients, the active ingredients are ACE liposomes, acetyl hexapeptide-8, snake venom peptides, and bifid yeast fermentation product lysate, the ACE liposomes are Lips-014 ACE liposomes, the content of the thickener in the liquid complex is 0.24wt%; the content of the moisturizer in the liquid complex is 8wt%; the content of the preservative in the liquid complex is 0.35wt%; the content of ACE liposomes in the liquid complex is 1.5wt%, the content of acetyl hexapeptide-8 in the liquid complex is 0.005wt%, the content of snake venom peptides in the liquid complex is 0.01wt%, the content of bifid yeast fermentation product lysate in the liquid complex is 1.5wt%; and the balance is water.

[0046] The liquid composite prepared in Example 1: an agent, a thickener, a humectant, a preservative and water. The agent includes an active substance, which is ACE liposomes, acetyl hexapeptide-8, snake venom peptides, and a bifid yeast fermentation product lysate. The ACE liposomes are Lips-014 ACE liposomes, and the content of ACE liposomes in the liquid composite is 1.5wt%, the content of acetyl hexapeptide-8 in the liquid composite is 0.005wt%, the content of snake venom peptides in the liquid composite is 0.01wt%, and the content of bifid yeast fermentation product lysate in the liquid composite is 1.5wt%; the thickener is carbomer, and the content of the thickener in the liquid composite is 0.24wt%; the humectant is glycerol, and the content of the humectant in the liquid composite is 8wt%; the preservative is a raspberry ketone system, and the content of the preservative in the liquid composite is 0.35wt%; and the balance is water.

[0047] Example 2: A method for preparing a liquid composite The difference between this embodiment and embodiment 1 is that the effector further includes an active agent, which is a succinate derivative, and the content of the succinate derivative in the liquid compound is 0.009 wt%.

[0048] Preparation of maleic acid ester: Trimethylolpropane was added to maleic anhydride at 70°C and reacted at 90°C for 4 hours to obtain maleic acid ester. The amount of trimethylolpropane used was 100 wt% of maleic anhydride.

[0049] Preparation of succinate derivatives: Sodium hydroxide and 2-aminoethanol hydrogen sulfate are added to deionized water, stirred and mixed, and then maleate and ethanol are added at 40°C, reacted for 4 hours, and after the reaction is completed, the precipitate is cooled and precipitated, filtered, washed, and distilled under reduced pressure to obtain succinate derivatives. The amount of sodium hydroxide used is 40wt% of deionized water, the amount of 2-aminoethanol hydrogen sulfate used is 50wt% of deionized water, the amount of 2-aminoethanol hydrogen sulfate used is 25wt% of maleate, and the amount of anhydrous ethanol used is 150wt% of maleate.

[0050] The liquid composite prepared in Example 2: an effector, a thickener, a moisturizer, a preservative and water. The effector includes an active substance and an active agent, the active substance is ACE liposome, acetyl hexapeptide-8, a snake venom peptide, and a bifid yeast fermentation product lysate, the ACE liposome is Lips-014 ACE liposome, the content of ACE liposome in the liquid composite is 1.5wt%, the content of acetyl hexapeptide-8 in the liquid composite is 0.005wt%, the content of snake venom peptide in the liquid composite is 0.01wt%, and the content of bifid yeast fermentation product lysate in the liquid composite is 1.5wt%; the active agent is a succinate derivative, and the content of the succinate derivative in the liquid composite is 0.009wt%; the thickener is carbomer, and the content of the thickener in the liquid composite is 0.24wt%; the moisturizer is glycerol, and the content of the moisturizer in the liquid composite is 8wt%; the preservative is a raspberry ketone system, and the content of the preservative in the liquid composite is 0.35wt%; the balance is water.

[0051] Example 3: A method for preparing a liquid composite The difference between this embodiment and embodiment 1 is that the effector further includes an active agent, which is a succinate derivative, and the content of the succinate derivative in the liquid compound is 0.03 wt%.

[0052] The liquid composite prepared in Example 3: an effector, a thickener, a moisturizer, a preservative and water. The effector includes an active substance and an active agent, the active substance is ACE liposome, acetyl hexapeptide-8, a snake venom peptide, and a bifid yeast fermentation product lysate, the ACE liposome is Lips-014 ACE liposome, the content of ACE liposome in the liquid composite is 1.5wt%, the content of acetyl hexapeptide-8 in the liquid composite is 0.005wt%, the content of snake venom peptide in the liquid composite is 0.01wt%, and the content of bifid yeast fermentation product lysate in the liquid composite is 1.5wt%; the active agent is a succinate derivative, and the content of the succinate derivative in the liquid composite is 0.03wt%; the thickener is carbomer, and the content of the thickener in the liquid composite is 0.24wt%; the moisturizer is glycerol, and the content of the moisturizer in the liquid composite is 8wt%; the preservative is a raspberry ketone system, and the content of the preservative in the liquid composite is 0.35wt%; the balance is water.

[0053] Example 4: A method for preparing a liquid composite The difference between this embodiment and embodiment 3 is that the active agent further comprises 1,2-propylene glycol alginate. The content of 1,2-propylene glycol alginate in the liquid composite is 0.003 wt%.

[0054] The liquid complex prepared in Example 4 includes an effector, a thickener, a moisturizer, a preservative and water. The effector includes an active substance and an active agent, the active substance is ACE liposome, acetyl hexapeptide-8, snake venom peptide, bifida yeast fermentation product lysate, and the ACE liposome is Lips-014 ACE liposomes, the content of ACE liposomes in the liquid complex is 1.5wt%, the content of acetyl hexapeptide-8 in the liquid complex is 0.005wt%, the content of snake venom peptide in the liquid complex is 0.01wt%, and the content of bifid yeast fermentation product lysate in the liquid complex is 1.5wt%; the active agents are succinate derivatives and alginate-1,2-propylene glycol ester, the content of succinate derivatives in the liquid complex is 0.03wt%, and the content of alginate-1,2-propylene glycol ester is 0.003wt%; the thickener is carbomer, and the content of the thickener in the liquid complex is 0.24wt%; the humectant is glycerol, and the content of the humectant in the liquid complex is 8wt%; the preservative is raspberry ketone system, and the content of the preservative in the liquid complex is 0.35wt%; the balance is water.

[0055] Example 5: A method for preparing a liquid composite The difference between this embodiment and embodiment 3 is that the active agent further comprises 1,2-propylene glycol alginate. The content of 1,2-propylene glycol alginate in the liquid composite is 0.01 wt%.

[0056] The liquid complex prepared in Example 5 includes a benefit agent, a thickener, a moisturizer, a preservative and water. The active agent includes active substances and active agents. The active substances are ACE liposomes, acetyl hexapeptide-8, snake venom peptides, and bifid yeast fermentation product lysate. The ACE liposomes are Lips-014 ACE liposomes. The content of ACE liposomes in the liquid complex is 1.5wt%, the content of acetyl hexapeptide-8 in the liquid complex is 0.005wt%, the content of snake venom peptides in the liquid complex is 0.01wt%, and the content of bifid yeast fermentation product lysate in the liquid complex is 1.5wt%; the active agents are succinate derivatives and alginate-1,2-propylene glycol ester. The content of succinate derivatives in the liquid complex is 0.03wt%, and the content of alginate-1,2-propylene glycol ester is 0.01wt%; the thickener is carbomer, and the content of the thickener in the liquid complex is 0.24wt%; the humectant is glycerin, and the content of the humectant in the liquid complex is 8wt%; the preservative is raspberry ketone system, and the content of the preservative in the liquid complex is 0.35wt%; and the balance is water.

[0057] Comparative Example 1: A method for preparing a liquid composite The difference between this comparative example and Example 2 is that the content of the succinate derivative in the liquid composite is 0.001 wt %.

[0058] Comparative Example 1 Liquid complex prepared: utilitarian, thickener, moisturizer, preservative and water. The utilitarian includes active ingredients and active agents, the active ingredients are ACE liposomes, acetyl hexapeptide-8, snake venom peptides, bifid yeast fermentation product lysate, ACE liposomes are Lips-014 ACE liposomes, the content of ACE liposomes in the liquid complex is 1.5wt%, the content of acetyl hexapeptide-8 in the liquid complex is 0.005wt%, the content of snake venom peptides in the liquid complex is 0.01wt%, and the content of bifid yeast fermentation product lysate in the liquid complex is 1.5wt%; the active agent is a succinate derivative, and the content of the succinate derivative in the liquid complex is 0.001wt%; the thickener is carbomer, and the content of the thickener in the liquid complex is 0.24wt%; the moisturizer is glycerol, and the content of the moisturizer in the liquid complex is 8wt%; the preservative is a raspberry ketone system, and the content of the preservative in the liquid complex is 0.35wt%; the balance is water.

[0059] Comparative Example 2: A method for preparing a liquid composite The difference between this comparative example and Example 2 is that no active substance is added to the liquid composite.

[0060] The liquid composite prepared in Comparative Example 1 includes an agent, a thickener, a moisturizer, a preservative, and water. The agent includes an active agent, which is a succinate derivative, and the content of the succinate derivative in the liquid composite is 0.009wt%; the thickener is carbomer, and the content of the thickener in the liquid composite is 0.24wt%; the moisturizer is glycerol, and the content of the moisturizer in the liquid composite is 8wt%; the preservative is a raspberry ketone system, and the content of the preservative in the liquid composite is 0.35wt%; the balance is water.

[0061] In the selection of ingredients of the liquid complex of the present invention, without affecting the technical effect of the present invention, glycerol, disodium EDTA, raspberry ketone, 1,2-hexanediol, xanthan gum, 1,2-pentanediol, carbomer, carboxymethyl deacetylated chitosan, arginine, dipropylene glycol, ACE liposomes, acetyl hexapeptide-8, snake venom peptide, oligopeptide-1, palmitoyl tripeptide-5, carnosine, and bifida yeast fermentation product lysate can be arbitrarily selected.

[0062] Test example: 1. Cytotoxicity test The present invention conducts a cytotoxicity test on the liquid complex prepared in Example 1, mixes the liquid complex in Example 1 with culture, and prepares 8 test groups of liquid complexes with different volume percentages: 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, 0.01953125%; a blank control group and a positive control group are set, the blank control group is a culture medium, and the positive control group is a culture medium with a mass fraction of 10% DMSO added, and the test group, the blank control group and the positive control group are contacted with the test cells, and the in vitro toxicity to the cells is evaluated by the test of the cell growth inhibition effect, and the safety of the base as a human body contact material is investigated. The test cells are human immortalized keratinocytes (HaCaT).

[0063] Table 1 Cytotoxicity test results Grouping Blank control Positive Control Test Group 1 Test Group 2 Test Group 3 Test Group 4 Test Group 5 Test Group 6 Test Group 7 Test Group 8 Mean 0.8846 0.2446 0.8339 0.8001 0.7761 0.7766 0.7732 0.7505 0.7720 0.7860 SD 2.64% 0.38% 0.52% 0.72% 0.72% 0.74% 0.72% 1.01% 0.66% 0.53% CV 2.99% 1.55% 0.63% 0.90% 0.93% 0.96% 0.93% 1.34% 0.86% 0.67% Survival rate 100% 27.65% 94.27% 90.45% 87.73% 87.79% 87.41% 84.84% 87.27% 88.85% p-value / <0.0001 0.0154 0.0012 0.0003 0.0003 0.0002 0.0001 0.0002 0.0004 The cytotoxicity test results of the liquid composite prepared in Example 1 of the present invention are shown in Table 1, wherein the volume percentages of the liquid composites corresponding to test group 1, test group 2, test group 3, test group 4, test group 5, test group 6, test group 7, and test group 8 are 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125%, respectively; The cell viability of the group at 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625% and 0.01953125% volume percentages were 94.27%, 90.45%, 87.73%, 87.79%, 87.41%, 84.84%, 87.27%, 88.85%, all greater than 70%, and the tested liquid complex had no cytotoxicity. The present invention conducted a cytotoxicity test on the succinate derivative prepared in Example 2, and prepared the liquid complex by the preparation method of Example 2, changed the succinate derivative in the liquid complex to 1wt%, and then added it to the cell culture medium at a volume percentage of 2.50% of the liquid complex, and the obtained cell viability was 92.51%, with no cytotoxicity.

[0064] 2. Cell proliferation test The present invention performs a cell proliferation test on the liquid complex prepared in Example 1, mixes the liquid complex of Example 1 with culture, and prepares 8 test groups of liquid complexes with different volume percentages: 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, 0.01953125%; sets a blank control group and a positive control group, the blank control group is a culture medium, and the positive control group is a culture medium with a mass fraction of 10% DMSO added, and the test group, the blank control group and the positive control group are contacted with the test cells, and the cell proliferation rate of HSF cells is calculated to evaluate the proliferation effect on the cells. The test cells are human skin fibroblasts (HSF).

[0065] Table 2 Cell proliferation test results Grouping Blank control Positive Control Test Group 1 Test Group 2 Test Group 3 Test Group 4 Test Group 5 Test Group 6 Test Group 7 Test Group 8 Mean 0.4411 0.5488 0.6203 0.6047 0.5569 0.531 0.5007 0.4998 0.4914 0.4274 SD 0.19% 0.95% 0.23% 1.08% 2.78% 1.00% 1.70% 1.65% 1.07% 1.61% CV 0.43% 1.73% 0.37% 1.78% 4.99% 1.89% 3.40% 3.30% 2.17% 3.77% Survival rate 100% 124.42% 140.64% 137.11% 126.25% 120.40% 113.51% 113.31% 111.40% 96.89% p-value / 0 0 0 0.002 0.0001 0.0038 0.0036 0.0013 0.2175 The cell proliferation test results of the liquid composite prepared in Example 1 of the present invention are shown in Table 2, wherein the volume percentages of the liquid composites corresponding to test group 1, test group 2, test group 3, test group 4, test group 5, test group 6, test group 7, and test group 8 are 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125%, respectively; the test groups have a significant cell proliferation promoting effect on human skin fibroblasts (HSF) at volume percentages of 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125, and 0.0390625%.

[0066] 3. Anti-inflammatory effect test The present invention uses Luminex200 liquid suspension chip instrument to detect the expression of inflammatory factors after human fibroblasts are treated with test samples. The present invention uses three different test samples to administer human fibroblasts, and after culturing in a carbon dioxide incubator at 37°C for 24 hours, the supernatant is collected in a new plate, and a protein chip study is performed to detect the expression level of cellular inflammatory factors. In the present invention, the above test is divided into 4 groups, each group contains 3 replicates, namely the negative control group, test group 1, test group 2, and test group 3; water is added to the negative control group, test group 1 is 0.5 vol% of the liquid complex prepared in Example 1, test group 2 is 0.5 vol% of the commercially available product 1, and test group 3 is 0.5 vol% of the commercially available product 2. Commercially available product 1 is Winona Revitalizing Repair Essence, and commercially available product 2 is Helena Green Bottle Series Essence.

[0067] This study detected the expression of 48 inflammatory factors. Figure 1-3 As shown in the figure, the results of the 8 inflammatory factors were analyzed for significance. Figure 4shown.

[0068] Table 3 Significance statistics of inflammatory factors

[0069] The statistical significance of the eight inflammatory factors in the present invention is shown in Table 3, among which test group 1, test group 2, and test group 3 all showed significant downregulation of the expression of CRO-α inflammatory factor. Through in-depth comparative studies of the three types of skin care essence products, it was found that test group 1 had the most significant inhibitory effect on inflammation at 0.5 vol%.

[0070] The present invention performs anti-inflammatory tests on the liquid complexes prepared in Examples 1-5 and Comparative Examples 1-2, sets a negative control group, which is water, and compares and analyzes the expression of inflammatory factors of MIF. The results are as follows: Figure 5 As shown, wherein S1 is Example 1, S2 is Example 2, S3 is Example 3, S4 is Example 4, S5 is Example 5, D1 is Comparative Example 1, D2 is Comparative Example 2, and NC is a negative control group. The present invention uses an agent, an adjuvant and water to prepare a liquid complex. The agent at least includes an active substance, and the adjuvant includes a thickener, a moisturizer and a preservative. The active substance can be acetyl hexapeptide-8, oligopeptide-1, snake venom peptide, carnosine, palmitoyl tripeptide-1, ACE liposome, bifida yeast fermentation product and lysate. At least one of the following, the liquid complex obtained by compounding the agent and the adjuvant has a good anti-inflammatory effect; an active agent can also be added to the agent. The active agent of the present invention can use a succinate derivative, and the succinate derivative is made of 2-aminoethanol hydrogen sulfate and maleate, and the maleate is made of The liquid compound obtained by using trimethylolpropane and maleic anhydride and the succinate derivatives, under the combination of active substances and adjuvants, has better anti-inflammatory ability and has a better effect of reducing the relative gene expression of MIF; the increase in the amount of succinate derivatives used increases the anti-inflammatory ability of the liquid compound, which can reduce the relative gene expression of MIF; when the amount of succinate derivatives used in the active agent is too low, the anti-inflammatory ability of the liquid compound cannot be enhanced, and the relative gene expression of MIF cannot be reduced; alginate-1,2-propylene glycol ester can also be added to the active agent of the present invention, and when alginate-1,2-propylene glycol ester and succinate derivatives are used as active agents together with active substances and adjuvants, the liquid compound obtained has better anti-inflammatory ability and has a better effect of reducing the relative gene expression of MIF. If the active substance is not used in the liquid compound, but only the active agent is added, the anti-inflammatory ability of the liquid compound obtained is poor, and the relative gene expression of MIF cannot be significantly reduced.

[0071] 4. Quantitative gene expression test for anti-aging effect The present invention uses Luminex 200 suspension chip multiplex detection system technology, combined with the QGP method, to detect and analyze the effects of three test samples on gene expression in human fibroblasts. The present invention uses three different test samples to administer HFF cells, at a rate of 8×10 4 The cells were plated in a 24-well plate at a density of 100 cells / well, with a volume of 0.5 ml per well. The cell plates were cultured in an incubator for 24 h.

[0072] In the present invention, the above test is divided into 4 groups, each group contains 3 replicates, namely negative control group, test group 1, test group 4, and test group 5; water is added to the negative control group, test group 1 is 0.5 vol% of the liquid complex prepared in Example 1, test group 4 is 0.5 vol% of commercially available product 3, and test group 5 is 0.5 vol% of commercially available product 4. Commercially available product 1 is Winona Revitalizing Repair Essence, and commercially available product 2 is Helena Green Treasure Bottle Series Essence. The content is 0.5 vol%. After 24 h of cultivation, the supernatant is removed, and 0.2 ml of cell lysis solution is added to the well plate containing HFF cells to lyse the cells. The lysed cells are stored in an environment of -80°C. Commercially available product 4 is a certain W essence, and commercially available product 5 is Helena Green Treasure Bottle Series Essence.

[0073] The present invention detected the expression of 41 genes in total, and the cells were treated with three test samples. The results of the whole gene were as follows: Figure 6-8 The study conducted a significant analysis of eight of the genes, COL3A1, COL1A1, FGF7, TIMP2, SOD2, NFE2L2, MMP1 and IL6. The results are shown in Fig. 9 and Table 4.

[0074] Table 4 Results of significance analysis of seven genes

[0075] 0.5vol% test group 1 can significantly upregulate the relative expression levels of COL3A1, COL1A1, and NFE2L2 genes (p<0.01), significantly upregulate the relative expression levels of FGF7 and TIMP2 genes (p<0.05), and significantly downregulate the relative expression level of MMP1 gene (p<0.01); 0.5vol% test group 5 can significantly upregulate the relative expression level of COL1A1 gene (p<0.01).

[0076] In summary, among test group 1, test group 4 and test group 5, test group 1 has a better regulatory effect on aging genes and has significant anti-aging ability.

[0077] The present invention performs an anti-aging test on the liquid composites prepared in Examples 1-5 and Comparative Examples 1-2, sets a negative control group, and the negative control group is water. The relative expression of the NFE2L2 gene is used for comparative analysis. The results are as follows: Fig.10 As shown, S1 is Example 1, S2 is Example 2, S3 is Example 3, S4 is Example 4, S5 is Example 5, D1 is Comparative Example 1, D2 is Comparative Example 2, and NC is a negative control group. The present invention uses an agent, an adjuvant and water to prepare a liquid complex. The agent at least includes an active substance, and the adjuvant includes a thickener, a moisturizer and a preservative. The active substance can be acetyl hexapeptide-8, oligopeptide-1, snake venom peptide, carnosine, palmitoyl tripeptide-1, ACE liposome, bifida yeast fermentation product and lysate. At least one of the products, through the compounding of the agent and the adjuvant, the obtained liquid complex has a good anti-aging effect; an active agent can also be added to the agent, and the active agent of the present invention can use a succinate derivative, and the succinate derivative is made of 2-aminoethanol hydrogen sulfate and maleate, and the maleate is made of trimethylolpropane and maleic anhydride, the use of succinate derivatives, under the compounding of active substances and adjuvants, the obtained liquid complex has better anti-aging ability and has a better effect on improving the relative gene expression of NFE2L2; the increase in the use of succinate derivatives, the anti-aging ability of the obtained liquid complex increases, and the relative gene expression of NFE2L2 can be increased; when the use of succinate derivatives in the active agent is too low, the anti-aging ability of the liquid complex cannot be enhanced, and the relative gene expression of NFE2L2 cannot be increased; alginate-1,2-propylene glycol ester can also be added to the active agent of the present invention, and alginate-1,2-propylene glycol ester and succinate derivatives are used as active agents together with active substances and adjuvants. The obtained liquid complex has better anti-aging ability and has a better effect on improving the relative gene expression of NFE2L2. If no active substance is used in the liquid complex, but only the active agent is added, the anti-aging ability of the obtained liquid complex is poor, and the relative gene expression of NFE2L2 cannot be significantly increased.

[0078] 5. Human skin patch test With reference to the 2015 Technical Specifications for Safety of Cosmetics, the liquid complex prepared in Example 1 was used as a test product for skin leave-on products to evaluate the irritation of cosmetics. The test method was a skin patch test, and 30 randomly distributed people aged 18-60 were tested.

[0079] Test method: Put the test product into the patch tester, the dosage is 0.025g, and cover the patch tester with the test product on the curved side of the subject's forearm with non-irritating cloth-based tape, and gently press it with the palm of your hand to make it evenly adhere to the skin surface, continue for 24 hours, remove the test patch tester, and observe the skin reaction after the indentation disappears 30 minutes later. If the result is negative, observe again 24 hours and 48 hours after the patch test.

[0080] Evaluation criteria: Grade 0: negative reaction; Grade 1: Suspicious reaction, only slight erythema; Grade 2: weak positive reaction, erythema, infiltration, edema, and papules may be present; Grade 3: Strong positive reaction, erythema, infiltration, edema, papules may be present, and the reaction may extend beyond the test area; Grade 4: Very strong positive reaction, obvious erythema, severe infiltration, edema, confluent herpes, and reaction beyond the test area.

[0081] Test results: Skin reactions were negative in all subjects.

[0082] The above test results show that the liquid complex prepared by the present invention is mild and non-irritating to the skin as a skin-retention product and is safe to use.

[0083] 6. Anti-inflammatory effect test after medical aesthetics 30 volunteers of light medical aesthetic post-operative projects such as photorejuvenation and water light injection were collected, with an age range of 20-50 years old. The liquid complex prepared in Example 1 was used as a test product 3 days after the operation. After cleaning the face before use, the test product was evenly applied to the face, and used continuously for 28 days, and the skin condition was observed on the 0th day, 14th day, and 28th day.

[0084] Test indicators: 6.1.TEWL value detection: TEWL refers to the transepidermal water loss and stratum corneum water content of the face. The lower the value, the higher the stratum corneum water content and the better the skin barrier function; otherwise, the worse it is.

[0085] TEWL values: healthy state (0 15), subhealthy state (15 25), disease state (>25).

[0086] Table 5 TEWL value test results

[0087] After using the test product for 28 days, the transepidermal water loss of the subjects was significantly reduced, indicating that the transepidermal water loss after continuous use of the test product was significantly improved compared with the initial value, with an improvement rate of 12.25%.

[0088] 6.2 Hemoglobin value detection: The hemoglobin content in the skin is determined by measuring the amount of reflection after a specific wavelength of light is shone on the human skin. The lower the hemoglobin content, the lighter the redness.

[0089] Table 6 Hemoglobin value test results

[0090] After using the test product for 28 days, the hemoglobin content of the subjects decreased significantly. This shows that after continuous use of the test product, the hemoglobin level has improved compared with the initial value. The improvement rate is 6.05%.

[0091] 6.3. Feedback on adverse reactions during use All 30 subjects used the test products as required at the prescribed time and no adverse reactions were observed.

[0092] The embodiments and / or implementation methods described above are only used to illustrate the preferred embodiments and / or implementation methods for realizing the technology of the present invention, and are not intended to limit the implementation methods of the technology of the present invention in any form. Any technical personnel in this field may make slight changes or modifications to other equivalent embodiments without departing from the scope of the technical means disclosed in the content of the present invention, but they should still be regarded as technologies or embodiments that are essentially the same as the present invention.

[0093] This article uses specific examples to illustrate the principles and implementation methods of this application. The description of the above embodiments is only used to help understand the method and its core ideas of this application. The above is only the preferred implementation method of this application. It should be pointed out that due to the limitations of textual expression and the objective existence of infinite specific structures, ordinary technicians in this technical field can make several improvements, modifications or changes without departing from the principles of this application, and can also combine the above technical features in an appropriate manner; these improvements, modifications, changes or combinations, or the direct application of the concept and technical solution of the invention to other occasions without improvement, should be regarded as the scope of protection of this application.

Claims

1. A liquid compound comprising: The invention relates to an agent and water, wherein the content of the agent in the liquid complex is 0.003-6.0 wt %; the agent comprises an active substance, and the active substance comprises at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom peptide, carnosine, palmitoyl tripeptide-1, palmitoyl tripeptide-5, ACE liposome, bifid yeast fermentation product and lysate.

2. A liquid compound according to claim 1, characterized in that: The liquid compound further comprises a thickener, which comprises at least one of carbomer, xanthan gum and sclerotium gum, and the content of the thickener in the liquid compound is 0.01-1.0 wt %.

3. A liquid compound according to claim 1, characterized in that: The liquid composite further comprises a moisturizer, which comprises at least one of glycerol, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, carboxymethyl cellulose and chitosan, and the content of the moisturizer in the liquid composite is 1-20 wt %.

4. A liquid compound according to claim 1, characterized in that: The liquid compound further comprises a preservative, which is a raspberry ketone system, and the content of the preservative in the liquid compound is 0.1-1.0 wt %.

5. A liquid compound according to claim 1, characterized in that: The utility agent further comprises an active agent, wherein the active agent comprises a succinate derivative, wherein the succinate derivative is prepared from 2-aminoethanol hydrogen sulfate and maleate, and the maleate is prepared from trimethylolpropane and maleic anhydride.

6. A liquid compound according to claim 5, characterized in that: The content of the active agent in the liquid compound is 0.003-1.0wt%; or, The content of active matter in the liquid composite is 0.003-5.0 wt %.

7. A liquid compound according to claim 5, characterized in that: In the preparation of the maleate, trimethylolpropane and maleic anhydride are mixed and reacted to obtain the maleate, and the amount of trimethylolpropane used is 50-150wt% of the maleic anhydride.

8. A liquid compound according to claim 5, characterized in that: In the preparation of the succinate derivative, 2-aminoethanol hydrogen sulfate and maleate are mixed in an ethanol aqueous solution containing sodium hydroxide, and reacted to obtain the succinate derivative; the amount of 2-aminoethanol hydrogen sulfate used is 20-30wt% of the maleate.

9. Use of the liquid complex according to any one of claims 1 to 8 in the preparation of anti-inflammatory cosmetics and / or anti-aging cosmetics and / or non-irritating products.

10. The use according to claim 9, characterized in that: The liquid complex further contains at least one of EDTA, disodium EDTA and amino acid.

Images